1. Search Result
Search Result
Results for "

repeats

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

2

Biochemical Assay Reagents

22

Peptides

2

Natural
Products

4

Recombinant Proteins

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-141799

    Ligands for Target Protein for PROTAC Cancer
    Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs .
    Dimethyl-F-OICR-9429-COOH
  • HY-129087

    Apoptosis Cancer
    BC-1258, an F-box/LRR-repeat protein 2 (FBXL2) activator, can stabilize and upregulate FBXL2 levels. BC-1258 induces apoptosis of tumorigenic cells, and profoundly inhibits tumor formation in mice .
    BC-​1258
  • HY-19820A

    Akt Ser/Thr Protease Neurological Disease Cancer
    NSC45586 sodium is an inhibitor of pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP). NSC45586 sodium targets the PP2C phosphatase domain in PHLPP1 and PHLPP2. NSC45586 sodium can activate AKT in neurons .
    NSC45586 sodium
  • HY-150400

    PROTACs Histone Methyltransferase Cancer
    XF056-132 free base is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader .
    XF056-132 free base
  • HY-157332

    Histone Methyltransferase Cancer
    WDR5-IN-7 (Compound 22) is an orally bioavailable benzoxazepinone-based WD repeat domain 5 (WDR5) inhibitor. WDR5-IN-7 can be used for the research of anti-cancer .
    WDR5-IN-7
  • HY-163941

    DNA/RNA Synthesis Cancer
    GSK_WRN2 is a potent and selective covalent WRN helicase inhibitor that suppresses replication stress caused by DNA (TA)n dinucleotide repeat expansions. GSK_WRN2 can be used to study microsatellite instability (MSI) cancers .
    GSK_WRN2
  • HY-141798

    Ligands for Target Protein for PROTAC Cancer
    OICR-9429-N-C2-NH2 is a ligand for Wd40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1, intermediate 2. OICR-9429-N-C2-NH2 can be used in the synthesis of PROTACs .
    OICR-9429-N-C2-NH2
  • HY-P10636

    LRRK2 Others
    Nictide is a peptide substrate of LRRK2 (leucine-rich repeat protein kinase-2). Nictide can be phosphorylated by the activated LRRK2[G2019S] with a Km of 10 μM .
    Nictide
  • HY-19820

    Akt Ser/Thr Protease Neurological Disease Cancer
    NSC45586 is an inhibitor of pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP). NSC45586 targets the PP2C phosphatase domain in PHLPP1 and PHLPP2. NSC45586 can activate AKT in neurons .
    NSC45586
  • HY-148353

    LRRK2 Neurological Disease
    PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC50 value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .
    PF-06455943
  • HY-16993
    OICR-9429
    5+ Cited Publications

    Histone Methyltransferase Apoptosis Cancer
    OICR-9429 is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
    OICR-9429
  • HY-P2516

    Tau Protein Neurological Disease
    Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein .
    Tau Peptide (275-305) (Repeat 2 domain)
  • HY-P4924

    Tau Protein Neurological Disease
    Tau Peptide (244-274) (Repeat 1 Domain) is aTau fragment.
    Tau Peptide (244-274) (Repeat 1 Domain)
  • HY-P4927

    Tau Protein Neurological Disease
    Tau Peptide (245-274) (Repeat 1 Domain) is aTau fragment.
    Tau Peptide (245-274) (Repeat 1 Domain)
  • HY-P4966

    Tau Protein Neurological Disease
    Tau Peptide (306-336) (Repeat 3 Domain) is aTau fragment.
    Tau Peptide (306-336) (Repeat 3 Domain)
  • HY-19347

    WD-Repeat Protein 5-0103

    Histone Methyltransferase Cancer
    WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with Kd of 450 nM.
    WDR5-0103
  • HY-134562

    LRRK2 Neurological Disease
    PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor .
    PF-06371900
  • HY-N4192

    Others Cardiovascular Disease Cancer
    Toringin, a bioflavonoid, is isolated from the bark of Docyniopsis tschonoski. Toringin progressively decreases not only the cis-effect of the expanded CTG repeats but cytotoxicity as well. Exposure to isosakuranetin, Toringin rescues PC12 neuronal cells. Flavonoids are efficacious for ameliorating the RNA gain of function caused by expanded CTG repeats, and have various biological activities and beneficial actions against cancers, coronary heart disease, among other pathologies .
    Toringin
  • HY-P1896

    HSP Infection Neurological Disease Cancer
    Hsp70-derived octapeptide is a conserved octapeptide of the C-terminal end of Hsp70, which physically interacts with tetratricopeptide repeat (TPR) motifs .
    Hsp70-derived octapeptide
  • HY-150403

    PROTACs Histone Methyltransferase Cancer
    XF067-68 is a PROTAC for targeted degradation of WD40 repeat domain protein 5 (WDR5) (extracted from patent WO2019246570A1) .
    XF067-68
  • HY-P4808

    Amyloid-β Autophagy Neurological Disease
    PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein .
    PHF6
  • HY-160228

    Toll-like Receptor (TLR) Inflammation/Immunology
    ORN 02 is a synthetic single-stranded U-rich RNA and contains 6 repeats of UUAU sequence motif. The AU-rich oligoribonucleotides (ORNs) are able to stimulate TLR8 .
    ORN 02
  • HY-160228A

    Toll-like Receptor (TLR) Inflammation/Immunology
    ORN 02 (sodium) is a synthetic single-stranded U-rich RNA and contains 6 repeats of UUAU sequence motif. The AU-rich oligoribonucleotides (ORNs) are able to stimulate TLR8 .
    ORN 02 sodium
  • HY-160227A

    Toll-like Receptor (TLR) Inflammation/Immunology
    ORN 06 (sodium) s a synthetic single-stranded U-rich RNA and contains 6 repeats of the UUGU sequence motif. The GU-rich oligoribonucleotides (ORNs) are able to stimulate TLR7 .
    ORN 06 sodium
  • HY-141482

    E1/E2/E3 Enzyme Cancer
    WSB1 Degrader 1 is a poten and orally active WSB1 (WD repeat and SOCS box-containing 1) degrader. WSB1 Degrader 1 has anticancer metastatic effects .
    WSB1 Degrader 1
  • HY-P4808A

    Amyloid-β Autophagy Neurological Disease
    PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein .
    PHF6 TFA
  • HY-120085
    PFE-360
    2 Publications Verification

    PF-06685360

    LRRK2 Neurological Disease
    PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC50 of 2.3 nM in vivo .
    PFE-360
  • HY-141878

    PROTACs Neurological Disease
    di-Ellipticine-RIBOTAC is a dual-function small molecule that reduces c9ALS/FTD r(G4C2) repeat expansion in vitro and in vivo amyotrophic lateral sclerosis (ALS ) models.
    di-Ellipticine-RIBOTAC
  • HY-15839
    UNC 669
    2 Publications Verification

    Epigenetic Reader Domain Cancer
    UNC 669, a ligand for a methyl-lysine binding domain, is a potent L3MBTL1 (IC50=4.2 uM) and L3MBTL3 (3.1 uM) inhibitor .
    UNC 669
  • HY-141796

    Histone Methyltransferase PROTACs Cancer
    MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a Kd of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects .
    MS67
  • HY-144074

    LRRK2 Neurological Disease
    LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .
    LRRK2-IN-4
  • HY-160229

    R-1075 sodium

    Toll-like Receptor (TLR) Infection
    ssRNA40 (sodium) is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide. ssRNA40 is a uridine-rich ssRNA derived from the HIV-1 long terminal repeat on activation of NK cells via TLR7/8 [1][2].
    ssRNA40 sodium
  • HY-13687
    IKK 16
    Maximum Cited Publications
    16 Publications Verification

    IKK LRRK2 Inflammation/Immunology
    IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC50s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC50 of 50 nM.
    IKK 16
  • HY-13687A
    IKK 16 hydrochloride
    Maximum Cited Publications
    16 Publications Verification

    IKK LRRK2 Inflammation/Immunology
    IKK 16 hydrochloride is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC50s of 40 nM, 70 nM and 200 nM, respectively . IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC50 of 50 nM .
    IKK 16 hydrochloride
  • HY-12282

    LRRK2 Neurological Disease
    GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .
    GNE-9605
  • HY-P4933

    Tau Protein Others
    Tau Peptide (255-314) (Repeat 2 Domain) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
    Tau Peptide (255-314) (Repeat 2 Domain) (human)
  • HY-100869

    Histone Methyltransferase Cancer
    MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM .
    MM-589
  • HY-124824

    Glyoxalase (GLO) Others
    Methyl gerfelin inhibits osteoclast differentiation by binding 3 major cellular proteins: glyoxalase 1 (GLO1), sterol binding protein 2 (SCP2), and small glutamine-rich tetratricopeptide repeat containing protein A (SGTA). Methyl gerfelin is a potent GLO1 inhibitor related to the flavonoid class .
    Methyl gerfelin
  • HY-163942

    DNA/RNA Synthesis Cancer
    GSK_WRN4 is a WRN helicase inhibitor (pIC50=7.6) with anticancer activity. GSK_WRN4 selectively inhibits the growth of MSI tumor cells in vitro and in vivo by inducing DNA double-strand breaks, particularly at expanded TA repeats and DNA damage regions .
    GSK_WRN4
  • HY-100869A

    Histone Methyltransferase Cancer
    MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM .
    MM-589 TFA
  • HY-160227

    Toll-like Receptor (TLR) Inflammation/Immunology
    ORN 06 (Compound R-0006), a U-rich single-stranded RNA (containing 6 repeats of the UUG sequence motif), is a TLR7/8 agonist. ORN 06 stimulates human TLR7/8-mediated or murine TLR7-mediated immunity .
    ORN 06
  • HY-111753
    WDR5-IN-4
    3 Publications Verification

    Histone Methyltransferase Cancer
    WDR5-IN-4 is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity .
    WDR5-IN-4
  • HY-P1985A

    Notch Cardiovascular Disease Cancer
    Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .
    Notch 1 TFA
  • HY-111753A
    WDR5-IN-4 TFA
    3 Publications Verification

    Histone Methyltransferase Cancer
    WDR5-IN-4 TFA is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 TFA displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity .
    WDR5-IN-4 TFA
  • HY-150654

    Histone Methyltransferase Cancer
    WDR5-IN-5 is an orally active and selective inhibitor of WIN site of WD repeat domain 5 (WDR5). WDR5-IN-5 exhibits anti-proliferative activity towards cancer cells and good pharmacokinetics profile in mice. WDR5-IN-5 shows high affinity to WDR5 and the binding affinity Ki value <0.02 nM .
    WDR5-IN-5
  • HY-P5497

    HIV Others
    C34 peptide is a biological active peptide. (This C34 peptide, also known as HR2, belongs to the helical region of gp41 of HIV, C-terminal heptad repeat 2 (HR2) defined as C helix or C peptide. It is known that HIV-1 enters cells by membrane fusion, C34 gp41 peptide is a potent inhibitors of HIV-1 fusion.)
    C34 peptide
  • HY-153898

    Others Neurological Disease
    rTRD01 is a TDP-43 ligand that binds to TDP-43’s RRM1 and RRM2 domains (Kd=89 uM for TDP-43102–269). rTRD01 partially disrupts TDP-43’s interaction with the hexanucleotide RNA repeat of the disease-linked c9orf72 gene. rTRD01 can be used for the research of neurodegenerative diseases .
    rTRD01
  • HY-100869B

    Histone Methyltransferase Cancer
    MM-589 (racemic mixture) TFA, is a racemic mixture of MM-589 TFA (HY-100869A). MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM .
    MM-589 (racemic mixture ) (TFA)
  • HY-151441

    LRRK2 Neurological Disease
    LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier .
    LRRK2-IN-5
  • HY-151444

    LRRK2 Neurological Disease
    LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier .
    LRRK2-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: